Premier, a U.S. hospital purchasing group, has signed new agreements for drug-eluting stents (DES) with Abbott Laboratories and Johnson & Johnson's Cordis. .
The group's 13-month agreements with the two stent makers became effective on Jan. 1. Premier said the agreements are available to its acute-care and continuum-of-care members.
Owned by non-profit hospitals, Premier runs a purchasing network that serves more than 2,100 U.S. hospitals and 53,000 other healthcare sites.
DES currently represent a roughly $2 billion market in the United States, according to Dow Jones.